Core Insights - Mar Vista U.S. Quality Strategy reported a net-of-fees gain of +0.20% in Q4 2025, underperforming the Russell 1000® Index (+2.41%) and the S&P 500® Index (+2.65%) [1] - The U.S. equity market experienced strong momentum in 2025, marking its second consecutive year of double-digit gains, with a rapid recovery from a bear market dip in April [1] - The market leadership was dominated by Mega-cap stocks and AI-driven companies, leading to a narrowing of market leadership [1] Performance Analysis - Stock selection in the communication services, consumer discretionary, and financials sectors positively impacted performance, while selections in information technology, materials, and healthcare detracted from it [1] - Johnson & Johnson (NYSE: JNJ) was highlighted as one of the strongest-performing holdings, with a one-month return of 0.20% and a 52-week gain of 44.88% [2] - Johnson & Johnson's market capitalization stood at $505.28 billion as of January 12, 2026 [2] Company Insights - Johnson & Johnson's strong Q4 performance was attributed to robust financial results, upward guidance revisions, and growth in its pharmaceutical and medical technology segments [3] - The company is expected to achieve 5-7% revenue growth through 2030, which exceeds consensus estimates [3]